Despite remdesivir approval and 2 big buyouts, Gilead CEO Dan O’Day sees pay fall 35% from 2019

For all intents and purposes, 2020 was a busy year for Gilead. The big biotech pulled off two big acquisitions in Forty Seven and Immunomedics, continued seeing growth in HIV products despite expiring patents on Truvada and won the Covid-19 treatment race with a sharp pivot to remdesivir early in…

...

Click to view original post